Kunkel Lori Anne
SEC insider (Form 3/4/5 filer). CIK 0001536368. Director at Enliven Therapeutics, Inc. (ELVN) and 2 other issuers. 15 reported Form 4/5 transactions since Sep 2024; latest on Jul 6, 2026. Located in BURLINGAME, CA.
Companies Kunkel Lori Anne has filed insider reports for
- Enliven Therapeutics, Inc. (ELVN): Director
- Oric Pharmaceuticals, Inc. (ORIC): Director
- Nurix Therapeutics, Inc. (NRIX): Director
Kunkel Lori Anne
CIK: 0001536368
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (15 total)
- Jul 6, 2026ELVN
Enliven Therapeutics, Inc.
SaleDirect5.9K shares at avg. $50.84$299K - Jul 6, 2026ELVN
Enliven Therapeutics, Inc.
SaleDirect4.1K shares at avg. $49.98$205K - Jun 5, 2026ELVN
Enliven Therapeutics, Inc.
SaleDirect1.9K shares at avg. $35.36$66K - Jun 5, 2026ELVN
Enliven Therapeutics, Inc.
SaleDirect7.8K shares at avg. $34.28$267K - Jun 5, 2026ELVN
Enliven Therapeutics, Inc.
SaleDirect354 shares at avg. $35.82$13K - Feb 12, 2026ELVN
Enliven Therapeutics, Inc.
AwardDirectStock Option (right to buy)
17.1K shares- - Jan 2, 2026ORIC
Oric Pharmaceuticals, Inc.
AwardDirectStock Option (right to buy)
40K shares- - Dec 17, 2025ELVN
Enliven Therapeutics, Inc.
ExerciseDirect16K shares at avg. $1.12$18K - Dec 8, 2025ORIC
Oric Pharmaceuticals, Inc.
ExerciseDirect10K shares at avg. $7.90$79K - Dec 4, 2025ORIC
Oric Pharmaceuticals, Inc.
ExerciseDirect5.5K shares at avg. $3.75$21K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jul 6, 2026 |  ELVN Enliven Therapeutics, Inc. | Sale | 5,889 | $50.84 | $299,421 | Direct |
| Jul 6, 2026 | ELVN Enliven Therapeutics, Inc. | Sale | 4,111 | $49.98 | $205,482 | Direct |
| Jun 5, 2026 | ELVN Enliven Therapeutics, Inc. | Sale | 1,867 | $35.36 | $66,012 | Direct |
| Jun 5, 2026 | ELVN Enliven Therapeutics, Inc. | Sale | 7,779 | $34.28 | $266,659 | Direct |
| Jun 5, 2026 | ELVN Enliven Therapeutics, Inc. | Sale | 354 | $35.82 | $12,680 | Direct |
| Feb 12, 2026 | ELVN Enliven Therapeutics, Inc. | Award Stock Option (right to buy) | 17,126 | - | - | Direct |
| Jan 2, 2026 |  ORIC Oric Pharmaceuticals, Inc. | Award Stock Option (right to buy) | 40,000 | - | - | Direct |
| Dec 17, 2025 | ELVN Enliven Therapeutics, Inc. | Exercise | 15,958 | $1.12 | $17,873 | Direct |
| Dec 8, 2025 | ORIC Oric Pharmaceuticals, Inc. | Exercise | 10,000 | $7.90 | $79,000 | Direct |
| Dec 4, 2025 | ORIC Oric Pharmaceuticals, Inc. | Exercise | 5,534 | $3.75 | $20,753 | Direct |
1-10 of 15 transactions